

### Our Mission

*The mission of Friends of FSH Research is to accelerate the discoveries that will lead to treatments or cures for FSH Muscular Dystrophy*




### Our Vision

*That one day when FSH Muscular Dystrophy is diagnosed, the next words said are... "there is a treatment!"*

## 2025-26 Annual Report June 1, 2025 - May 31, 2026

### Total Research Grant funding reaches nearly \$10M!

Our 2026 "Rustle Up a Cure" Gala in January raised over \$900,000 for FSHD research. These funds were quickly invested in research projects across the globe including The Fred Hutch Cancer Center in Seattle, St. Louis University, University of Utah, Leiden University in the Netherlands, Newcastle University and King's College in England, Università Cattolica del Sacro Cuore in Rome and biotech companies Histone Therapeutics and Springbok Analytics. Grants totaling nearly \$880,000 were awarded by Friends in the fiscal year ending on May 31, 2026.



These achievements are a direct result of your support as a sponsor or donor, allowing us to continue to fund research that has the best chance of moving toward a treatment or cure at a faster pace and keeps researchers working in the face of funding cuts from federal organizations such as the National Institutes of Health.

*Thank you for choosing to invest with us to help improve the lives of those living with FSHD – a disease that slowly destroys skeletal muscles in over half a million women and men around the world.*


# 2024-25 Financial Summary

June 1, 2025 to May 31, 2026

## In the fiscal year ending May 31, 2026, Friends of FSH Research:

- Invested \$880,00 in 12 FSHD research projects in pursuit of a treatment or cure
- Continued support of novel research projects that may speed discoveries
- Continued support of the FSHD Clinical Trials Research Network and future clinical trials

*Thanks to the support of our sponsors and donors, the future is looking more hopeful than ever - a therapy is close at hand for families living with the debilitating effects of FSHD.*



## Balance Sheet as of May 31, 2025

Year-End Assets	\$656,250
Year-End Liabilities	\$1,102,000 <sup>1</sup>

<sup>1</sup>Funds committed to multi-year research projects.

### Board of Directors

Terry Colella – President  
Rick Colella – Treasurer  
Elisabeth Jas  
Erik Svenson

Brad Bagshaw – Vice President  
Lynn Fischer  
Shelli Kind  
Karl Voss

George Shaw – Secretary  
Chris Haven  
Amanda Rickard

### Scientific Advisory Board

Jeffrey S. Chamberlain, PhD – Director  
Monica Hayhurst Bennett, PhD  
Gregory J. Block, MSc, PhD  
Silvère M. van der Maarel, PhD

Jamshid Arjomand, PhD  
Dennis W. Shaw, MD  
Bruce M. Wentworth, PhD  
Premi Haynes, PhD

Amanda Rickard, BS  
Jeffery Statland, MD  
Kyoko Yokomori, PhD